Covid vaccine manufacturers start work on Omicron-tailored shots

BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target Omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on Monday.

The variant’s emergence has triggered a strong global response as countries worried that it could spread fast even in vaccinated populations impose travel curbs and other restrictions.

BioNTech SE said it had started work on a vaccine tailored to Omicron, along with partner Pfizer.

Meanwhile, Moderna Inc said it could take months to begin shipping such a vaccine, Chief Executive Officer Stephane Bancel told CNBC.

Bancel said the effectiveness of existing COVID-19 vaccines against the variant was currently not known, adding there should be more clarity in about two weeks.

Johnson & Johnson is also evaluating the effectiveness of its COVID-19 vaccine against Omicron, while also pursuing a vaccine specific to the variant.

“We have begun work to design and develop a new vaccine against Omicron and will rapidly progress it into clinical studies if needed,” said Mathai Mammen, global head of research for J&J’s pharmaceuticals unit.

A top South African infectious disease expert said Omicron appears to be more transmissible than previous variants, including to people with immunity from vaccination or prior infection.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor